Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer´s Disease
Posted Oct 02 2009 10:01pm
The Gammaglobulin Alzheimer’s Partnership Study (GAP)has added six new sites to its clinical trial.
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer´s Disease (AD).
Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
To read the inclusion/exclusion criteria and more about this Phase 3 clinical trial go here.
The study is being sponsored by National Institute on Aging (NIA), Alzheimer's Disease Cooperative Study (ADCS), and Baxter BioScience (Baxter Healthcare Corporation).
Bob DeMarco is the editor of the Alzheimer's Reading Room and an Alzheimer's caregiver. The Alzheimer's Reading Room is the number one website on the Internet for news, advice, and insight into Alzheimer's disease. Bob has written more than 800 articles with more than 18,000 links on the Internet. Bob resides in Delray Beach, FL.